Phentermine News and Research

RSS

Phentermine is a drug that decreases your appetite.

GLP-1 receptor activation linked to lower depression and bipolar disorder odds

Genetic analyses linked BMI-related GLP-1 receptor activation to better mental well-being and lower odds of major depressive disorder and bipolar disorder. The findings do not prove that GLP-1 receptor agonist drugs treat psychiatric conditions, and randomized clinical trials are still needed.

15 Jul 2026

Study links semaglutide and tirzepatide to fewer anxiety and depression diagnoses in obesity care

A US electronic health record study found that adults with obesity who started semaglutide or tirzepatide had lower recorded hazards of anxiety and depression than matched patients using naltrexone-bupropion. However, among adults without type 2 diabetes, tirzepatide was linked to higher recorded hazards of anxiety and insomnia than semaglutide, underscoring the need for cautious monitoring.

1 Jul 2026

Patients who stop GLP-1 drugs often restart or try alternatives

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing weight management strategies.

17 Mar 2026

New genetic test can help predict how people will respond to weight-loss medications

Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s.

17 Sep 2025

Brain’s energy control map offers blueprint for next-gen weight loss therapies

Scientists map how the brain integrates hormonal and neural signals from the body to control appetite, energy use, and reward pathways, revealing targets for next-generation anti-obesity drugs. This review highlights the interplay between neuroendocrine circuits, neuroplasticity, and pharmacotherapy for durable, non-aversive weight loss.

11 Aug 2025

What happens to your weight after quitting GLP-1 anti-obesity drugs?

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six months. Despite this rebound, most patients maintain some weight loss compared to baseline a year after discontinuation.

23 Jul 2025

Weight regain observed in patients after ending obesity drug treatment

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, finds a meta-analysis published in BMC Medicine.

22 Jul 2025

New findings highlight a shifting landscape for weight loss and glucose managing medications

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.

15 Apr 2025

Semaglutide linked to higher risk of vision problems, FDA data analysis shows

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher reporting rate of vision impairment. The findings call for further study into the ocular risks of this widely prescribed diabetes and weight loss drug.

8 Apr 2025

Older Americans support insurance coverage for obesity medications

A large majority of older Americans feel that health insurance – including Medicare – should cover anti-obesity medications, according to a new University of Michigan study.

27 Mar 2025

Early use of anti-obesity medication doubles weight loss

Adding an anti-obesity medication just one month after behavioral therapy begins-rather than waiting the currently recommended six months-can more than double weight loss for patients who struggle initially with lifestyle changes alone, according to new research published in Nature Medicine from a team at the Perelman School of Medicine at the University of Pennsylvania.

18 Mar 2025

Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugs

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest influences prescription trends.

3 Feb 2025

GLP1R medications show promise in reducing suicidal ideation among adolescents with obesity

Adolescents treated with GLP1R drugs for obesity exhibit fewer suicidal thoughts, indicating potential mental health benefits of these medications.

17 Oct 2024

How diet affects metabolism and the gut microbiome

In a recent review, researchers explored advances in molecular nutrition, focusing on pharmaceutical and dietary interventions for energy balance and their interactions with the gut microbiome. They also discussed emerging dietary patterns and the implications of microbiome research on nutrition.

28 Jul 2024

Semaglutide linked to increased risk of severe eye condition NAION in new study

Research shows semaglutide users face a significantly higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) compared to users of other medications for diabetes and obesity.

8 Jul 2024

The USPSTF recommend clinicians refer children and adolescents 6 years or older with a high BMI to intensive behavioral interventions

Researchers at the USPSTF discussed the high prevalence of obesity among adolescents and children in the US, particularly among certain ethnic groups and those from lower-income families.

21 Jun 2024

Underutilized obesity treatments could transform patient health

When someone has obesity, losing even 5% of their body weight can make a major difference in their health -- especially if they can keep from regaining it.

21 Feb 2024

Poll: Vast majority of older adults think health insurers should cover obesity medications

The vast majority of older adults – 83% -- think health insurers should cover medications that can help people with obesity manage their weight, a new poll of people age 50 to 80 finds.

13 Dec 2023

Tirzepatide shows success in maintaining weight loss in obese adults

Study finds that the anti-obesity medication tirzepatide effectively maintains weight loss in obese adults, offering a promising approach to managing obesity and related health complications.

12 Dec 2023

Research reveals a potential gap in recommended care for people with obesity and overweight

By being undiagnosed or untreated, a significant fraction of people with obesity or overweight are not getting the recommended care, despite an increase in new treatment options, according to research being presented on June 17 at ENDO 2023, the Endocrine Society's annual meeting in Chicago, Ill.

18 Jun 2023